tbuckley/cabot-search huggingface dataset:
Voluntary Purchasing Pools: A Market Model for Improving Access, Quality, and Cost in Health Care
Authors: K M Haddad
Journal: Annals of Internal Medicine (1996)

States and small businesses have been rapidly establishing voluntary health care purchasing pools during the past few years.Purchasing pools can decrease health care costs, improve access for some small businesses and individual persons, allow greater choice among health care plans, and provide continuity of care. Purchasing pools also help to even the balance of power in the health care market-place, which has come increasingly under the control of huge proprietary managed care corporations. This position paper of the American College of Physicians discusses how a system of well-designed voluntary purchasing pools can help protect the integrity of health care in the emerging managed care marketplace.
Abstract PO-057: Targeting ErbB2 degradation via the ubiquitin–proteasome pathway to inhibit the metastasis of pancreatic cancer
Authors: Bo Zhang, Fei Teng, Nengming Lin
Journal: Cancer Research (2021)

Abstract Objective: Pancreatic cancer is currently one of the most lethal human cancers and continues to be a major unsolved health problem in the 21st century. Since pancreatic cancer has a high metastatic potential, chemotherapy is inevitable for most pancreatic cancer patients, whereas the clinical responses to anticancer agents are not satisfied. In this work, we designed and synthesized a novel compound, termed as 6-MPA, and found that 6-MPA could improve the proteasomal degradation of ErbB2 pancreatic cancer cells. Methods: The inhibitory effects of 6-MPA on migration and invasion was measured by scratch experiment, wound healing assay and transwell experiment. Clone formation and CCK-8 assay was used to determine the cytotoxicity of 6-MPA. Real-time PCR and western blotting was used to determine the expression of indicated genes or proteins respectively. Immunoprecipitation was used to characterize protein–protein interactions. Results: 4, 8, and 16 μM of 6-MPA exhibited an inhibitory effects on the migration of SW1990 cells and the inhibition rates reached 40.2±10.1%, 58.2±11.2%, and 65.2±9.9% in vitro, respectively. RNA-seq showed that 6-MPA treatment manipulated ErbB2 level and its downstream PI3K/AKT/mTOR signaling pathways, which was verified by western blotting assay. Treatment with 6-MPA could enhance the interaction between ErbB2 and ubiquitin, and thus promote the proteasomal degradation of ErbB2. Conclusion: In this study, we obtained a novel small molecule 6-MPA, which could specifically degrade ErbB2 through the activation of protein ubiquitinination. And we found that 6-MPA possessed potent inhibitory effects on migration and invasion of pancreatic cancer cells. Therefore, our work illustrated a novel structure skeleton that could be used to target ErbB2, and potentially suppressed the metastasis of pancreatic cancer. Citation Format: Bo Zhang, Fei Teng, Nengming Lin. Targeting ErbB2 degradation via the ubiquitin–proteasome pathway to inhibit the metastasis of pancreatic cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-057.
PHF6 and JAK3 Mutations Cooperatively Drive T-Cell Acute Lymphoblastic Leukemia Progression
Authors: Xiaomin Wang, Shengnan Yuan, Shuaibing Hou, Yanjie Lan, Tengxiao Guo, Fei Zhao, Yajing Chu, Cheng Tao, Weiping Yuan
Journal: Blood (2021)
A Phase Ib Study of Linperlisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Authors: Jie Jin, Hong Cen, Keshu Zhou, Xiaohong Xu, Fei Li, Haiyan Yang, Zhiming Li, Hanying Bao, Zusheng Xu, Lugui Qiu, Yang Shu, Fei Li, Zhen Wang
Journal: Blood (2021)
Abstract PO-038: LAMC2: New player in stemness and tumor progression in pancreatic cancer
Authors: Donatella Delle Cave, Tea Teresa Iavazzo, Maria Mangini, Gennaro Andolfi, Teresa Pirozzi, Annalisa Di Domenico, Annachiara De Luca, Enza Lonardo
Journal: Cancer Research (2021)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a devastating and essentially incurable disease, typically characterized by high chemoresistance and metastatic spread attributable to cancer stem cells (CSCs). This subpopulation is critical for tumor initiation and recurrence, but the mechanism through which they acquire metastatic traits is not well understood. Hence, targeting the CSC niche and their plasticity could be a complementary therapeutic strategy against cancer. Laminin subunit-γ-2 (LAMC2) is an epithelial basement membrane protein, which controls cell motility and adhesion and is widely expressed in the majority of human tumors. However, its role in PDAC remains largely unknown. In several patient cohorts we observed that high levels of LAMC2 significantly correlated with shorter overall survival. In addition, the tissue microarray analysis on PDAC sections revealed prognostic significance of LAMC2 expression in tumor with high grade of aggressiveness (i.e., G2 and G3). To determine the role of LAMC2 in sustaining tumorigenicity, we knocked down it in patient-derived xenografts (PDX) cells using lentiviral shRNA constructs. The silencing of LAMC2 resulted in decreased self-renewal, invasiveness, tumorigenicity and gemcitabine resistance both in vitro and in vivo. To identify or track the LAMC2 tumor cell population in an intact environment we engineered primary PDAC cells that carry EGFP cassette knocked in the LAMC2 locus through the CRISPR-Cas9 technique. Analysis of LAMC2-EGFP+ cells isolated from tumor demonstrated that these cells express a gene program similar to that of highly metastatic stem cells and that they initiate and propagate both the primary tumor and the metastasis to recipient mice very efficiently compared to their counterpart. In conclusion, we identified a highly metastatic subpopulation of cancer stem cells, characterized by high levels of LAMC2. Strategies aimed at targeting the LAMC2 population may be effective in reducing tumor aggressiveness in combination with conventional therapy. Citation Format: Donatella Delle Cave, Tea Teresa Iavazzo, Maria Mangini, Gennaro Andolfi, Teresa Pirozzi, Annalisa Di Domenico, Annachiara De Luca, Enza Lonardo. LAMC2: New player in stemness and tumor progression in pancreatic cancer [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-038.
Tc Buster Transposon Engineered CLL-1 CAR-NK Cells Efficiently Target Acute Myeloid Leukemia
Authors: Mark Gurney, Eimear O'Reilly, Sarah Corcoran, Sarah Brophy, David Hardwicke, Janusz Krawczyk, David Hermanson, Richard W. Childs, Eva Szegezdi, Michael E. O'Dwyer
Journal: Blood (2021)
Impact of the Use of Bendamustine Immediately before the Collection of Hematopoietic Stem Cells in Lymphoma. a Study By the Geltamo Group
Authors: Mariana Bastos-Oreiro, Javier Anguita, José Fernández, Ana Pilar Gonzalez, Raul Córdoba, Ana Isabel Jiminez Ubieto, Daniel Garcia, Carolina Martínez-Laperche, Valeria Delgado, Jose Garcia-Arroba, Antonio Salar, Juan-Manuel Sancho
Journal: Blood (2021)
The Genetic Architecture of Obsessive-Compulsive Disorder: Contribution of Liability to OCD From Alleles Across the Frequency Spectrum
Authors: Behrang Mahjani, Lambertus Klei, Manuel Mattheisen, Matthew W. Halvorsen, Abraham Reichenberg, Kathryn Roeder, Nancy L. Pedersen, Julia Boberg, Elles de Schipper, Cynthia M. Bulik, Mikael Landén, Bengt Fundín, David Mataix-Cols, Sven Sandin, Christina M. Hultman, James J. Crowley, Joseph D. Buxbaum, Christian Rück, Bernie Devlin, Dorothy E. Grice
Journal: American Journal of Psychiatry (2021)

Obsessive-compulsive disorder (OCD) is known to be substantially heritable; however, the contribution of genetic variation across the allele frequency spectrum to this heritability remains uncertain. The authors used two new homogeneous cohorts to estimate the heritability of OCD from inherited genetic variation and contrasted the results with those of previous studies.The sample consisted of 2,090 Swedish-born individuals diagnosed with OCD and 4,567 control subjects, all genotyped for common genetic variants, specifically >400,000 single-nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) ≥0.01. Using genotypes of these SNPs to estimate distant familial relationships among individuals, the authors estimated the heritability of OCD, both overall and partitioned according to MAF bins.Narrow-sense heritability of OCD was estimated at 29% (SE=4%). The estimate was robust, varying only modestly under different models. Contrary to an earlier study, however, SNPs with MAF between 0.01 and 0.05 accounted for 10% of heritability, and estimated heritability per MAF bin roughly followed expectations based on a simple model for SNP-based heritability.These results indicate that common inherited risk variation (MAF ≥0.01) accounts for most of the heritable variation in OCD. SNPs with low MAF contribute meaningfully to the heritability of OCD, and the results are consistent with expectation under the "infinitesimal model" (also referred to as the "polygenic model"), where risk is influenced by a large number of loci across the genome and across MAF bins.
A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Myelofibrosis
Authors: Prithviraj Bose, Taghi Manshouri, Sharon D. Bledsoe, Nitin Jain, Lucia Masarova, Naveen Pemmaraju, Nakiuda Hall, Mary Ann Richie, Xuemei Wang, Hagop Kantarjian, Zeev E. Estrov, Srdan Verstovsek
Journal: Blood (2021)
A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes
Authors: David M Ross, Alejandro Arbelaez, Lynette C.Y. Chee, Chun Yew Fong, Devendra Hiwase, George Kannourakis, John Kwan, James Liang, Anish Puliyayil, Hannah Rose, Shuhying Tan, Tse-Chieh Teh, David Alan Westerman, Joel Wight, Chris Rovaldi, Elissa M. Furutani, Adrienne Gaggi, Ying Jiang, Jenn Lachey, Harveen Dhillon Natarajan, Claudia Ordonez
Journal: Blood (2021)
Loss of an Immunodominant HLA-Α *01:01 Restricted Epitope for CD8+ Cytotoxic T Lymphocytes (CTLs) in the Delta Variant of COVID-19: An Example of Immunologic Escape and Implications for Immunologic Treatment
Authors: Neal Flomenberg, Dolores Grosso, Yuri Sykulev, Nadezhda Anikeyeva, Yanping Huang, Michael Sun, Kaitlin Keck, Allyson O'Connor, Alexis Peedin, Julie Karp, Phyllis Flomenberg, AnnaMaria Chang, Patricia Henwood, Kristin Rising, Neda Nikbakht, Liza McGuire, Samuel Flomenberg, Ryan Saadi, John L. Wagner
Journal: Blood (2021)
Safety and Efficacy Profile of Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)
Authors: Sairah Ahmed, Ian W. Flinn, Matthew Mei, Peter A. Riedell, Philippe Armand, Natalie S Grover, Andreas Engert, Natalia Lapteva, Paul I. Nadler, Aung Myo, Helen E. Heslop
Journal: Blood (2021)
Characterization of the Humoral and Cellular Immune Response Against the Natural Infection By Sars-Cov-2 in Oncohematological Patients with Post-COVID19 Autologous Transplantation
Authors: Adrián Sánchez-Tornero, Lorena Vigon, Guiomar Casado-Fernandez, Javier Garcia-Pérez, Elena Mateos, Magdalena Corona De Lapuerta, Sara Rodriguez-Mora, Monserrat Torres, María Aranzazú Murciano-Antón, Mayte Pérez-Olmeida, Javier Lopez Jimenez, Maria Rosa López-Huertas, Maria Teresa Coiras, Valentín Garcia-Gutiérrez
Journal: Blood (2021)
Back health bill amendments to make England smoke free by 2030, medical leaders urge
Authors: Zosia Kmietowicz
Journal: BMJ (2021)

More than 650 health experts and activists are calling on the government to back amendments in the forthcoming Health and Care Bill that they say will help England become smoke free by 2030.

Two years ago ministers pledged to make England smoke free by 2030, underpinned by making smoked tobacco obsolete and helping smokers quit or to move to reduced risk products such as e-cigarettes.1 But the government has still not published its new Tobacco Control Plan to deliver the smoke free ambition, which it pledged to publish this year, or the post-implementation review of tobacco regulations, which it was required in law to do …
Carbapenem Antibiotics Promote Mucus Degradation By <i>Bacteroides</i> and Aggravate Graft-Versus-Host Disease
Authors: Eiko Hayase, Tomo Hayase, Chia-Chi Chang, Takahiko Miyama, Jennifer L. Karmouch, Wen-Bin Tsai, Mohamed A. Jamal, Robert R. Jenq
Journal: Blood (2021)
Germinal Center B Cells Derived from <i>TET2</i>-Mutated Clonal Hematopoiesis Provide a Microenviromental Niche for Tumor Cells in Angioimmunoblastic T-Cell Lymphoma
Authors: Manabu Fujisawa, Tran B. Nguyen, Yoshiaki Abe, Yasuhito Suehara, Kota Fukumoto, Sakurako Suma, Kensuke Usuki, Kentaro Narita, Kosei Matsue, Naoya Nakamura, Shumpei Ishikawa, Fumihito Miura, Takashi Ito, Ayako Suzuki, Yutaka Suzuki, Satoru Takahashi, Shigeru Chiba, Mamiko Sakata-Yanagimoto
Journal: Blood (2021)
Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia
Authors: Peter Clifton, David Sullivan, John Baker, Christian Schwabe, Susan Thackwray, Russell Scott, James Hamilton, Armando J Lira Pineda, Bruce Given, Stacey Melquist, Iris Chen, Javier San Martin, Gerald F Watts, Ira J Goldberg, Josh Knowles, Daniel Gaudet, Robert A Hegele, Christie M Ballantyne
Journal: Circulation (2021)

Background: Familial chylomicronemia syndrome (FCS) is an ultrarare condition caused by biallelic pathogenic DNA variants in lipolysis-associated genes, resulting in severe hypertriglyceridemia (HTG) and associated with high risk of acute pancreatitis with few therapeutic options. In a 16-week Phase 1 study (NCT03783377), subcutaneously administered ARO-APOC3 reduced serum apolipoprotein C3 (APOC3) and TG in healthy volunteers and participants (pts) with HTG and was well tolerated. Purpose: To report on the safety/pharmacodynamic (PD) effects of ARO-APOC3 in both FCS pts with biallelic pathogenic variants and pts with severely elevated TG at screening (&gt;880 mg/dL) but without biallelic pathogenic variants (chylomicronemia (MCM)). Methods: Four genetically confirmed FCS pts received 50 mg ARO-APOC3 and 26 MCM pts received 10, 25, 50, or 100 mg ARO-APOC3 on Days 1 and 29. Since similar PD responses were observed among MCM pts, results were pooled across dose levels. Safety and PD responses were examined. Maximal mean/median changes from baseline for APOC3, TG, non-HDL-C, and HDL-C were reported. Results: Baseline/demographics were comparable between groups, except for mean BMI (22.1 [FCS] and 30.5 [MCM] kg/m 2 ), and mean baseline HDL-C , which were lower in FCS pts (Table 1) (p&lt;0.0001 for both). Mean APOC3 was reduced by 98% and 96% in FCS and MCM pts, respectively. Both groups also showed similar maximum median reductions in TG of 91% and 90%, respectively. Similar to the full study, non-HDL-C was reduced and HDL-C increased with treatment in both groups (Table 1). AEs were similar between groups, suggesting a comparable safety profile. Conclusions: In patients with severe HTG, ARO-APOC3 was safe, and consistently decreased APOC3, TG, and non-HDL-C, and increased HDL-C, regardless of underlying genetic cause of HTG, and may represent a promising RNAi therapeutic for the treatment of severe HTG.
The Effect of Voxelotor on Exercise Capacity of Youths with Sickle Cell Anemia
Authors: Vivian Phan, Laura Caldarera, Ana Lucia Cortez, Kari Wheeler, Sandra K. Larkin, Sangah Nancy Park, Robin Yates Dulman, Noravy Briere, Angela Lewis, Frans A. Kuypers, Jared Hershenson, Elizabeth Yang
Journal: Blood (2021)
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis
Authors: Jonathan E Brammer, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Eric D Jacobsen, Giuseppe Gritti, Debra Litwak, David Cohan, Danica J Katz, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz
Journal: Blood (2021)
Avidity-Engineered CD3 Engaging DARPin ® Targeting Three Tumor Associated Antigens Induce Strong and Specific T Cell Dependent Killing of AML Cells with Potential for Improved Safety
Authors: Matteo Bianchi, Nina Reschke, Christian Reichen, Stefanie Fischer, Yvonne Grübler, Aline Eggenschwiler, Jennifer Krieg, Kyriaki Ioannou, Simone Ragusa, Thamar Looser, Patricia Spitzli, Christel Herzog, Denis Villemagne, Yvonne Kaufmann, Mirela Matzner, Alienor Auge, Martin Hänggi, Waleed Ali, Marco Franchini, Vladimir Kirkin, Bernd Schlereth, Ursina Luethi, Adrian Ochsenbein, Carsten Riether, Daniel Steiner, Anne Goubier
Journal: Blood (2021)
Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)
Authors: Michael Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Krish Patel, Cyrus Khan, Nancy L. Bartlett, Gloria Iacoboni, Mark Hertzberg, Sirpa Leppä, Eric Van Den Neste, Monica Tani, Guillaume Cartron, Antonio Salar, David Perez-Callejo, Linda Lundberg, James Relf, Emma Clark, Kathryn Humphrey, Martin Hutchings
Journal: Blood (2021)
A versatile platform for the tumor-targeted delivery of immune checkpoint-blocking immunoglobin G
Authors: Jie Fan, Yanru Feng, Ze Tao, Jie Chen, Hao Yang, Qiuxiao Shi, Zhao Li, Tianshan She, Heng Li, Youmei Jin, Jingqiu Cheng, Xiaofeng Lu
Journal: Journal of Controlled Release (2021)
Early Evaluation of the Use of Crizanlizumab in Sickle Cell Disease: A National Alliance of Sickle Cell Centers Study
Authors: Julie Kanter, Gerhard Hellemann, Alice J. Cohen, Deepa Manwani, Modupe Idowu, Stephanie Guarino, Sana Saif Ur Rehman, Marsha Treadwell, E. Leila Jerome Clay, Amma Owusu-Ansah, Jane A. Little, Payal Desai, Mohan Madisetti, Sophie M. Lanzkron
Journal: Blood (2021)
Induced Pluripotent Stem Cell-Derived Gamma Delta CAR-T Cells for Cancer Immunotherapy
Authors: Mark A Wallet, Toshinobu Nishimura, Christina Del Casale, Andriana Lebid, Brenda Salantes, Katherine Santostefano, Sydney Bucher, Mark Mendonca, Marilda Beqiri, Lucas J Thompson, Barry A Morse, Hillary Millar Quinn, Luis Borges
Journal: Blood (2021)
Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study
Authors: Yair Herishanu, Neta Goldschmidt, Gilad Itchaki, Itai Levi, Ariel Aviv, Riva Fineman, Najib Dally, Tamar Tadmor, Rosa Ruchlemer, Uri Abadi, Lev Shvidel, Andrei Braester, Raanan Cohen, Neta Frankel, Keren Ofek, Jenia Berelovich, Moshe Grunspan, Ohad Benjamini
Journal: Blood (2021)
Katz Frailty Syndrom has no Predictive Value in Low-Risk Patients Undergoing Transcatheter Aortic Valve Implantation
Authors: Katarzyna Byczkowska
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

Background: Aortic stenosis is a disease of the elderly people, with multiple comorbidities and often with the frailty syndrome. Therefore, we decided that frailty as a clinical factor requires precise characterization as it is a valuable supplement to the risk stratification in transcatheter aortic Valve implantation (TAVI). Objective: The aim of our study was to evaluate the prognostic value of the Katz frailty scale in patients undergoing TAVI in relation to the risk of mortality assessed with the STS scale. Material and methods: The study included 105 patients with severe aortic stenosis (AS) treated with TAVI at the Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior. In our group, the Katz frailty syndrome confirmed in all patients, and 48% in the advanced stage. Results: Statistical analysis showed a significant difference between survival and Katz frailty score before TAVI. Analysis using Cox's model confirmed a significant prognostic value for the Katz frailty syndrome before TAVI. Patients with moderate to severe frailty on the Katz score (values ≤ 4) had a 13,68 times higher risk of death per year compared to the group with Katz frailty syndrome ≥ 5. Multivariate regression analysis indicated that Katz frailty score and STS score were prognostically significant factors of cardiovascular death in patients undergoing TAVI. Conclusion: The Katz frailty score had a significant prognostic value in the high- and intermediate risk patients. Katz frailty score and STS risk score significantly correlated with the risk of death from cardiovascular causes in frailty patients undergoing TAVI.
Audio Interview: Covid-19 in Brazil and New Evidence for Vaccinating Younger Children
Authors: Eric J. Rubin, Lindsey R. Baden, Beatriz Grinsztejn, Stephen Morrissey
Journal: New England Journal of Medicine (2021)

Covid-19 in Brazil and New Evidence for Vaccinating Younger Children In this audio interview conducted on November 5, 2021, the editors are joined by Brazilian researcher Beatriz Grinsztejn to disc...
<i>DNMT3A</i>overgrowth syndrome is associated with the development of hematopoietic malignancies in children and young adults
Authors: Margaret A. Ferris, Amanda M. Smith, Sharon E. Heath, Eric J. Duncavage, Matthew Oberley, David Freyer, Robert Wynn, Sofia Douzgou, John M. Maris, Anne F. Reilly, Melinda D. Wu, Florence Choo, Roel B. Fiets, Saskia Koene, David H. Spencer, Christopher A. Miller, Marwan Shinawi, Timothy J. Ley
Journal: Blood (2021)

DNMT3A overgrowth syndrome (DOS, also known as Tatton-Brown-Rahman Syndrome [TBRS]) is an overgrowth syndrome caused by de novo germline mutations in the gene encoding the de novo DNA-methyltransferase 3A (DNMT3A).2][3][4] Affected individuals shared distinctive facial features, intellectual disability, obesity, and tall stature.Although somatic mutations in DNMT3A are among the most common initiating events for patients with normal karyotype acute myeloid leukemia (AML) and clonal hematopoiesis, 5-9 mutations of DNMT3A are rarely found in pediatric patients with AML. 10
Abstract 9853: Covid-19 Myocarditis: Quantitative Analysis of the Inflammatory Infiltrate
Authors: Richard S Vander Heide, Sharon E Fox
Journal: Circulation (2021)

Introduction: COVID-19 has a significant effect upon the cardiovascular system including small amounts of myocyte death in some patients resulting in elevated troponin levels. While a number of different cardiovascular histopathologies have been described at post-mortem examination, the incidence of typical viral myocarditis in COVID-19 positive patients appears very low. Hypothesis: We hypothesized that COVID-19 causes a different type of inflammatory cell response that although different, may still cause significant negative effects on the cardiovascular system. Methods: Using immunoperoxidase staining, we characterized and quantified the number of CD3 + , CD4 + , CD8 + , CD68 + staining cells in 10 COVID-19 hearts, 10 hearts matched for age and underlying comorbidities, and 5 hearts with autopsy proven typical inflammatory myocarditis. Results: The results demonstrate a skewed distribution of the number of CD68+ cells in COVID-19 hearts, with upper quantiles showing a significant increase as compared to both matched control hearts, and those with myocarditis. In contrast, hearts from typical inflammatory myocarditis contained increased numbers of CD4+, and CD8+ cells compared to both COVID-19 and control cohorts. . Conclusions: In conclusion, the presence of an increased number of CD68+ cells suggests that COVID-19 may incite a form of myocarditis different from typical viral myocarditis, and associated with diffusely infiltrative cells of monocytes/macrophage lineage.
Longitudinal Distribution of Lipid-Rich Plaque in Nonculprit Lesions
Authors: Evan Shlofmitz, Gary S. Mintz, Rebecca Torguson, Cheng Zhang, Corey Shea, Priti Shah, Gheorghe Doros, Ziad A. Ali, Andre Artis, Varinder Singh, William Skinner, Tim Ten Cate, Carlo Di Mario, Hector M. Garcia-Garcia, Ron Waksman
Journal: JACC. Cardiovascular imaging (2021)